ASN's Mission

ASN leads the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: SA-PO1061

Eicosapentaenoic Acid (EPA) Powerfully Prevents the Progression for Both Renal Dysfunction and Atherosclerosis in CKD Patients Due to Benign Nephrosclerosis

Session Information

Category: Health Maintenance, Nutrition, and Metabolism

  • 1302 Health Maintenance, Nutrition, and Metabolism: Clinical

Authors

  • Inoue, Yoshihiko, Division of Nephrology, Department of Medicine, Showa University Fujigaoka Hospital, Yokohama, Japan
  • Kawashima, Eri, Showa University Fujigaoka Hospital, Yokohama, Kanagawa, Japan
  • Inui, Kiyoko, Division of Nephrology, Department of Medicine, Showa University Fujigaoka Hospital, Yokohama, Japan
  • Yoshimura, Ashio, Shinyokohama Daiichi Clinic, Yokohama, Japan
  • Koiwa, Fumihiko, Division of Nephrology, Department of Medicine, Showa University Fujigaoka Hospital, Yokohama, Japan
Background

Effect of EPA for CKD patients is not fully known. We studied the efficacy of EPA to prevent the progression of both renal impairment and atherosclerosis in CKD stage 3-4 patients due to benign nephrosclerosis (BNS).

Methods

28 CKD stage 3-4 patients due to BNS with dyslipidemia were followed for 5years after the start of EPA treatment (EPA (+): n=20) or treatment without EPA (EPA (-): n=8). The dosage of 1800 mg/day of EPA was newly prescribed in EPA treatment group. T-cho, LDL-cho, Triglycerides (TG), eGFR, the amount of proteinuria, EPA, arachidonic acid (AA), Dihomo-gamma-linolenic acid (DGLA) and docosa hexaenoic acid (DHA) were examined. Both right and left (RL) brachial-ankle pulse wave velocity (baPWV), RL maximum carotid intima-media thickness (max IMT), RL maximum carotid plaque thickness and RL ankle-brachial index (ABI) were evaluated at before treatment (baseline), after every year and at the end of the study (5-year).

Results

EPA, EPA/AA ratio, TG. RL baPWV, and RL max IMT showed significant improvement and eGFR did not decrease at 5-year in EPA treatment group (table 1). Furthermore, both EPA and DHA levels were significantly low in eGFR exacerbation patients group (n=7) compared with the improvement group (n=13) at both baseline and 5-year in EPA treatment group. EPA treatment patients showing the highest EPA levels at baseline (EPA: 107.5±15.2μg/ml, n=5) showed significant improvement in both eGFR and baPWV compared with those with the lowest EPA levels (31.0±9.2 μg/ml, n=5). There was no difference on both plaque thickness and ABI between baseline and 5-year.

Conclusion

EPA powerfully prevents the progression of both renal dysfunction and the atherosclerotic change in CKD stage 3-4 patients due to BNS.

Table 1
 EPA treatment (+)EPA treatment (-)
 BaselineEnd of the study (5-year)PBaselineEnd of the study (5-year)P
EPA (μg/ml)65.6±30.5250.0±66.2<0.0565.9±25.862.1±24.6N.S.
EPA/AA0.38±0.151.47±0.46<0.050.38±0.150.36±0.15N.S.
TG (mg/dl)215.2±104.1137.0±45.1<0.05187.9±67.2202.6±98.7N.S.
Right baPWV (cm/s)1724.3±291.51596.5±203.7<0.051705.3±218.41762.3±145.0N.S.
Left baPWV (cm/s)1762.8±338.51613.4±218.9<0.051704.8±196.21775.9±124.1N.S.
Right max IMT (mm)0.96±0.270.77±0.11<0.050.96±0.150.99±0.16N.S.
Left max IMT (mm)0.92±0.230.78±0.10<0.050.96±0.160.98±0.15N.S.
eGFR (ml/min/1.73m2)41.1±10.343.9±12.6N.S.42.9±9.139.9±10.0<0.05